The pharmaceutical industry is witnessing a major shift in glucose therapy with the introduction of GLP-1 transdermal devices. These groundbreaking delivery systems offer a possibly easy choice to injections for individuals managing diabetes mellitus type 2. By circumventing the requirement for f